{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:00:09Z","timestamp":1770462009676,"version":"3.49.0"},"reference-count":28,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Clinical Innovation Project of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","award":["19XHCR3D"],"award-info":[{"award-number":["19XHCR3D"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32130036"],"award-info":[{"award-number":["32130036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874181"],"award-info":[{"award-number":["81874181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91940305"],"award-info":[{"award-number":["91940305"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\"Jiao Tong University Star\" Medical-Industrial Crossover Research Project of Shanghai Jiao Tong University","award":["YG2022ZD006"],"award-info":[{"award-number":["YG2022ZD006"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,2,16]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gallbladder cancer (GBC) is an aggressive type of digestive system cancer with a dismal outcome. Given the lack of effective treatment options, the disease rapidly reoccurs and 5-year survival rate is &lt;5%. Our team previously found that a significant percentage of GBC tissues harboured mutations of the ErbB-related pathway. Afatinib is a chemically synthesised drug specifically targeting the ErbB pathway mutations. However, its efficacy in the treatment of patients with GBC remains unknown. Circulating tumour DNA (ctDNA) refers to a proportion of cell-free DNA in the blood which is released by apoptotic and necrotic cells from tumours in situ, metastatic foci or circulating tumour cells. ctDNA-based liquid biopsy is a non-invasive pathological detection method that offers additional value to evaluate the therapeutic efficacy of antitumour drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We conduct a multicentre and randomised study on afatinib combined with gemcitabine and oxaliplatin (GEMOX) in patients with ErbB pathway mutated GBC. Clinical and biological evaluation involving ErbB pathway ctDNA detection will be made during the 3-year follow-up after participation. The primary objective of this clinical trial is to evaluate the clinical efficacy of afatinib. Disease-free survival is the primary end point and will be correlated with plasma ctDNA of patients in the treatment with afatinib. In addition, we will evaluate the sensitivity and specificity of plasma ctDNA for monitoring tumour recurrence and progression. Finally, we will assess the safety of afatinib by keeping an eye on the safety indicators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study was approved by the medical-ethical review committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. The clinical trials results, even inconclusive, will be published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04183712\">NCT04183712<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-061892","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T11:05:24Z","timestamp":1677582324000},"page":"e061892","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04183712","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mao","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China"},{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China"},{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China"},{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuya","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China"},{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatao","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenguang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China"},{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-An","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China"},{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maolan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China"},{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-0185","authenticated-orcid":false,"given":"Yingbin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China"},{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"2025121410453383000_13.2.e061892.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"2025121410453383000_13.2.e061892.2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S37357"},{"key":"2025121410453383000_13.2.e061892.3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4240\/wjgs.v13.i2.176","article-title":"Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer: results from 24 hospitals in China","volume":"13","author":"Ren","year":"2021","journal-title":"World J Gastrointest Surg"},{"key":"2025121410453383000_13.2.e061892.4","first-page":"697","article-title":"Analysis of treatment modalities and prognosis of patients with gallbladder cancer in China from 2010 to 2017","volume":"58","author":"Ren","year":"2020","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"2025121410453383000_13.2.e061892.5","first-page":"99","article-title":"A largescale multicenter retrospective study of current surgical treatment modalities and pathological characteristics of patients with gallbladder cancer in china\uff1aA report of 4,345 cases","volume":"41","author":"Sun X H","year":"2021","journal-title":"Chin J Pract Surg"},{"key":"2025121410453383000_13.2.e061892.6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","article-title":"Overview of current targeted therapy in gallbladder cancer","volume":"5","author":"Song","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2025121410453383000_13.2.e061892.7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.21037\/hbsn-20-846","article-title":"Modified Folfirinox for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen","volume":"10","author":"Cui","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2025121410453383000_13.2.e061892.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.07.143"},{"key":"2025121410453383000_13.2.e061892.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70247-3"},{"key":"2025121410453383000_13.2.e061892.10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.343"},{"key":"2025121410453383000_13.2.e061892.11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605458"},{"key":"2025121410453383000_13.2.e061892.12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/bjc.2013.801","article-title":"S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma","volume":"110","author":"El-Khoueiry","year":"2014","journal-title":"Br J Cancer"},{"key":"2025121410453383000_13.2.e061892.13","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3030"},{"key":"2025121410453383000_13.2.e061892.14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316039"},{"key":"2025121410453383000_13.2.e061892.15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14737140.2018.1510324","article-title":"Current and future therapies for targeting HER2 mutations in gastrointestinal cancer","volume":"18","author":"El Dika","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025121410453383000_13.2.e061892.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"2025121410453383000_13.2.e061892.17","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/ijc.31916","article-title":"Erbb2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer","volume":"144","author":"Iyer","year":"2019","journal-title":"Int J Cancer"},{"key":"2025121410453383000_13.2.e061892.18","first-page":"59","article-title":"Synovioanalysis (\u201c liquid biopsy \u201d)","volume":"71","author":"Sorrells","year":"1974","journal-title":"J Ark Med Soc"},{"key":"2025121410453383000_13.2.e061892.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.01.006"},{"key":"2025121410453383000_13.2.e061892.20","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201744147"},{"key":"2025121410453383000_13.2.e061892.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.10.007"},{"key":"2025121410453383000_13.2.e061892.22","first-page":"241","article-title":"Nuclear acids in human blood plasma","volume":"142","author":"MANDEL","year":"1948","journal-title":"C R Seances Soc Biol Fil"},{"key":"2025121410453383000_13.2.e061892.23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"Forshew","year":"2012","journal-title":"Sci Transl Med"},{"key":"2025121410453383000_13.2.e061892.24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308859"},{"key":"2025121410453383000_13.2.e061892.25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/0284186X.2019.1701201","article-title":"Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers","volume":"59","author":"Jensen","year":"2020","journal-title":"Acta Oncol"},{"key":"2025121410453383000_13.2.e061892.26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2017.10.032","article-title":"Her2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer","volume":"88","author":"Wang","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025121410453383000_13.2.e061892.27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001942","article-title":"Cell-Free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025121410453383000_13.2.e061892.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00050"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-061892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:45:39Z","timestamp":1765737939000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-061892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,28]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bmjopen-2022-061892"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-061892","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}